Cystic Fibrosis Gene Editing Group
The focus of the lab is to use CRISPR gene editing to correct CF causing mutations and explore routes to develop this for therapeutic application.
The lab is funded by Science Foundation Ireland, CF Trust (UK) and CF Foundation (USA), and currently has three post-docs and two PhD students.
We are currently working on Base Editing, Homology-Independent Targets Integration (HITI) Homology-Directed Repair (HDR) and Prime editing as outlined in recent publications
https://pubmed.ncbi.nlm.nih.gov/35313109/ – CRISPR for respiratory medicine (2022)
https://pubmed.ncbi.nlm.nih.gov/34103250/ – CF gene editing (2022)
https://pubmed.ncbi.nlm.nih.gov/34031549/ – Prime Editing (2021)
https://pubmed.ncbi.nlm.nih.gov/31117296/ – Base Editing and Disease (2019)
https://pubmed.ncbi.nlm.nih.gov/29233638/ – Gene Editing and Stem Cells (2018)
I also serve as European Editor for Gene Therapy https://www.nature.com/gt/
Patrick HarrisonPrincipal Investigator
Department of Physiology, School of Medicine 00353214901405